Jackson Charlotte, Hsia Yingfen, Bielicki Julia A, Ellis Sally, Stephens Peter, Wong Ian C K, Sharland Mike
Paediatric Infectious Diseases Research Group, Institute of Infection and Immunity, St George's, University of London, London, UK.
Paediatric Pharmacology and Paediatric Infectious Diseases, University Children's Hospital Basel, Basel, Switzerland.
BMJ Glob Health. 2019 Feb 27;4(1):e001241. doi: 10.1136/bmjgh-2018-001241. eCollection 2019.
Understanding patterns of antibiotic consumption is essential to ensure access to appropriate antibiotics when needed and to minimise overuse, which can lead to antibiotic resistance. We aimed to describe changes in global antibiotic consumption between 2011 and 2015.
We analysed wholesale data on total antibiotic sales and antibiotics sold as child-appropriate formulations (CAFs), stratified by country income level (low/middle-income and high-income countries (LMICs and HICs)). The volume of antibiotics sold per year was recorded for 36 LMICs and 39 HICs, measured in standard units (SU: 1 SU is equivalent to a single tablet, capsule or 5 mL ampoule/vial/oral suspension) and SU per person, overall and as CAFs. Changes over time were quantified as percentage changes and compound annual growth rates in consumption per person. Analyses were conducted separately for total sales, sales of antibiotics in the Access and Watch groups of the WHO's Essential Medicines List for children 2017, for amoxicillin and amoxicillin with clavulanic acid.
Antibiotic consumption increased slightly between 2011 and 2015, from 6.85×10 SU to 7.44×10 SU overall and from 1.66×10 SU to 1.78×10 SU for CAFs. However, trends differed between countries and for specific antibiotics; for example, consumption of amoxicillin as CAFs changed little in LMICs and HICs, but that of amoxicillin with clavulanic acid increased by 6.8% per year in LMICs and decreased by 1.0% per year in HICs.
As measured in standard units in sales data, the rate of increase in global antibiotic consumption may be slowing. However, the trends appear to differ between countries and drugs. In the absence of routine surveillance of antibiotic use in many countries, these data provide important indicators of trends in consumption which should be confirmed in national and local studies of prescribing.
了解抗生素消费模式对于确保在需要时能够获取适当的抗生素并尽量减少过度使用至关重要,过度使用可能会导致抗生素耐药性。我们旨在描述2011年至2015年期间全球抗生素消费的变化情况。
我们分析了抗生素总销售额以及作为儿童适用剂型(CAF)销售的抗生素的批发数据,按国家收入水平(低收入/中等收入和高收入国家(LMICs和HICs))进行分层。记录了36个低收入和中等收入国家以及39个高收入国家每年销售的抗生素数量,以标准单位(SU:1 SU相当于一片药、一粒胶囊或5毫升安瓿/小瓶/口服混悬液)以及人均SU来衡量,包括总体情况和作为CAF的情况。随时间的变化以人均消费量的百分比变化和复合年增长率来量化。分别对总销售额、世界卫生组织2017年儿童基本药物清单中“准入”和“观察”组抗生素的销售额、阿莫西林以及阿莫西林克拉维酸进行了分析。
2011年至2015年期间,抗生素消费总体上略有增加,从6.85×10 SU增至7.44×10 SU,作为CAF的抗生素从1.66×10 SU增至1.78×10 SU。然而,不同国家以及特定抗生素的趋势有所不同;例如,作为CAF的阿莫西林在低收入和中等收入国家以及高收入国家的消费量变化不大,但阿莫西林克拉维酸在低收入和中等收入国家每年增长6.8%,在高收入国家每年下降1.0%。
根据销售数据中的标准单位衡量,全球抗生素消费的增长率可能正在放缓。然而,不同国家和药物的趋势似乎有所不同。由于许多国家缺乏对抗生素使用的常规监测,这些数据提供了重要消费趋势指标,应在国家和地方的处方研究中得到证实。